Importance The association between sodium-glucose transport protein 2 inhibitor (SGLT2i)
use and the incidence of acute kidney injury (AKI) remains controversial. The benefits of …

Importance Sodium-glucose cotransport protein 2 inhibitors (SGLT-2is) have demonstrated
associations with positive kidney-related and cardiovascular outcomes in patients with type …

Aim To assess the possible risk of acute kidney injury (AKI) with the use of sodium‐glucose
co‐transporter‐2 inhibitors (SGLT2‐i) as well as changes in estimated glomerular filtration …

Rationale & Objective Sodium/glucose cotransporter 2 (SGLT2) inhibitors slow the
progression of chronic kidney disease and prevent heart failure events. However, SGLT2 …

Rationale & Objective Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been found
to have many benefits for patients with type 2 diabetes. However, whether SGLT2 inhibitors …

Abstract Three, multicentre, large‐scale, randomized, placebo‐controlled trials of
cardiovascular outcomes with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors have …

BACKGROUND: Regulatory agencies warn about the risk of acute kidney injury (AKI) after
the initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Our objective was to …

OBJECTIVE Sodium-glucose cotransporter-2 (SGLT2) inhibitors are new medications that
improve cardiovascular and renal outcomes in patients with type 2 diabetes (T2D). However …

Purpose The sodium–glucose cotransporter-2 (SGLT2) inhibitors have changed the
treatment of type 2 diabetes mellitus. Several studies evaluated SGLT2 inhibitor-related …

Results In the 18 trials with a total of 2051 AKI events (range: 1–300) among 156,690
patients with type 2 diabetes only, our network meta-analysis showed that SGLT2 inhibitors …